Breathe Well Live Well
|
Vectura and Janssen Enter Global Partnership for Asthma, COPD
Lung Disease News Asthma is a chronic respiratory disease characterized by bronchial spasms of the lungs, resulting in causing difficulty in breathing. Attacks are commonly triggered by allergic reactions, irritants, and cold air. Chronic obstructive pulmonary disease … |
View full post on asthma – Google News
|
Vectura Inks Asthma/COPD License Agreement with Janssen
Genetic Engineering & Biotechnology News Vectura, a respiratory product development company, has entered a license agreement with Janssen Biotech to exclusively develop anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will initially focus on the development of a … |
View full post on asthma – Google News
|
Britain's Vectura collaborates with Janssen in asthma, COPD
Yahoo News LONDON (Reuters) – Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday. The collaboration will kick off with the development of a drug candidate for … Vectura Signs Global Development And Licence Deal With Janssen In Asthma … Vectura links with Janssen on asthma/COPD drug development J&J and Vectura sign asthma/COPD deal |
View full post on asthma – Google News
|
Britain's Vectura collaborates with Janssen in asthma, COPD
Reuters Janssen, a unit of Johnson & Johnson, will then use Vectura's dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, a market worth in excess of $46 billion worldwide, Vectura said … Vectura Signs Global Development And Licence Deal With Janssen In Asthma … Vectura links with Janssen on asthma/COPD drug development Vectura In Deal With Johnson & Johnson's Janssen Biotech For Asthma |
View full post on asthma – Google News